Pre-earnings options volume in Vertex is normal with calls leading puts 7:4. Implied volatility suggests the market is anticipating a move near ...

The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations , with sales up 15.7% year on year to $2.91 billion. The company ...

Adjusted earnings of $1.04 billion, or $3.98 per share, fell from $1.1 billion, or $4.20 per share, a year earlier, slightly short of estimates. Vertex pointed to an increase in operating ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

For Q4, Vertex (NASDAQ:VRTX) reported non-GAAP EPS of $3.98 on net product revenue of $2.91B. Analysts, on average, had been expecting non-GAAP EPS of $4.02 on revenue of $2.78B. Looking ahead ...

Vertex's non-GAAP EPS decrease to $3.98, from $4.20 in the previous year, underscores these cost pressures. Expenses from the Alpine acquisition also affected net income and remain a potential ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Charles ...